Brexpiprazole

證據等級: L5

預測適應症: 10 個

Brexpiprazole: From Major Depressive Disorder to Dysthymic Disorder

One-Sentence Summary

Brexpiprazole is a serotonin-dopamine activity modulator (atypical antipsychotic) with established FDA approval for schizophrenia and as adjunctive therapy for major depressive disorder (MDD), though it is currently not marketed in the European Union or Taiwan. The TxGNN model predicts it may be effective for Dysthymic Disorder (now classified as Persistent Depressive Disorder, PDD), with 0 clinical trials and 0 publications directly addressing this specific indication — though mechanistic rationale and indirect evidence from MDD augmentation trials underpin the hypothesis.

Quick Overview

Item	Content
Original Indication	Schizophrenia; Adjunctive treatment of Major Depressive Disorder (FDA-approved; known from published literature — no EU/Taiwan regulatory record available)
Predicted New Indication	Dysthymic Disorder (Persistent Depressive Disorder)
TxGNN Prediction Score	98.53%
Evidence Level	L4
EU Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from regulatory sources in this evidence pack. Based on pharmacological information reported in published literature, brexpiprazole is a second-generation atypical antipsychotic classified as a serotonin-dopamine activity modulator. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A and α2C adrenergic receptors — a multi-receptor profile that differentiates it from older antipsychotics and produces a more balanced effect on mood, reward, and arousal circuits.

Dysthymic Disorder — now classified under DSM-5/ICD-11 as Persistent Depressive Disorder (PDD) — shares core neurobiology with MDD, including serotonin and dopamine system dysregulation, but features milder symptom severity and a substantially longer, more chronic disease course. Brexpiprazole’s D2 partial agonism theoretically fine-tunes dopamine reward circuit signaling to address the low-grade but persistent anhedonia and motivational impairment seen in PDD; its 5-HT1A agonism contributes to mood stabilization; and its 5-HT2A antagonism enhances prefrontal dopamine and norepinephrine release, supporting affect regulation. The α2C adrenergic antagonism further amplifies noradrenergic tone.

A clinically important advantage for the PDD context is brexpiprazole’s comparatively favorable metabolic and extrapyramidal tolerability profile relative to other augmentation agents such as quetiapine or olanzapine. Because PDD is a chronic condition requiring sustained treatment, this tolerability advantage is mechanistically and practically significant. Indirect clinical support comes from Phase 3 RCTs demonstrating meaningful efficacy in MDD augmentation (e.g., PMID 26301701); however, no clinical trials or publications have specifically targeted PDD or dysthymia as a primary indication to date.

Clinical Trial Evidence

Currently no related clinical trials registered for brexpiprazole in dysthymic disorder.

Literature Evidence

Currently no literature directly examining brexpiprazole in dysthymic disorder is available.

Note: Substantial literature exists for brexpiprazole in related depressive disorders (neurotic depression, melancholia, treatment-resistant MDD — see predicted indications ranked 5 and 6 in the full evidence pack). These include Phase 3 RCTs, systematic reviews, and network meta-analyses totalling over 20 publications. This body of evidence provides indirect mechanistic support for the dysthymia prediction but does not constitute direct evidence.

Safety Considerations

Please refer to the SmPC and relevant prescribing information for safety data. Key data gaps have been identified:

TFDA SmPC warnings and contraindications: Not retrieved (blocking gap — required for full safety evaluation)
Drug-drug interactions: No DDI records found in the query database

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic hypothesis is biologically plausible — PDD and MDD share the same 5-HT/DA dysregulation pathways, and brexpiprazole’s multi-receptor profile addresses the core neurobiology of chronic low-grade depression — but there are currently no clinical trials and no direct published evidence targeting dysthymic disorder specifically. The current evidence level (L4: mechanistic reasoning only) is insufficient to support a development or regulatory decision without further clinical data.

To proceed, the following is needed:

Retrieve full MOA data from DrugBank to formally document receptor binding profile and confirm mechanistic rationale
Obtain TFDA/EMA SmPC to assess contraindications, key warnings, and drug interaction profile (currently a blocking data gap)
Design a Phase 2 proof-of-concept study in adults with PDD (DSM-5 criteria) who have had inadequate response to ≥1 antidepressant
Pre-specify long-term tolerability monitoring plan (weight, metabolic panel, akathisia assessment, QTc) given the chronic treatment duration expected in PDD
Clarify regulatory pathway in target markets (EU/Taiwan), as brexpiprazole currently holds no authorizations in either jurisdiction
Evaluate whether MDD Phase 3 RCT data (e.g., NCT data referenced in PMID 26301701) can be leveraged as bridging evidence to support a PDD indication filing
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.